Cheng-Hao Tseng

Cheng-Hao Tseng

Auto-generated profile, based on publicly available information

Cheng-Hao Tseng

Division of Gastroenterology and Hepatology E‐Da Cancer Hospital Kaohsiung Taiwan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
YHYao‐Chun Hsu
Yao‐Chun Hsu
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
LMLein‐Ray Mo
Lein‐Ray Mo
MWMing-Shiang Wu
Ming-Shiang Wu
TYTzeng‐Huey Yang
Tzeng‐Huey Yang
CCChi‐Yang Chang
Chi‐Yang Chang
Summary: Background: There remains an unmet need for convenient biomarkers to assess the risks of discontinuing nucleos(t)ide analogues (NAs) in chronic hepatitis B (CHB).Aim: To investigate if hepatitis B core‐related antigen (HBcrAg) is an independent of surface antigen (HBsAg) for risk prediction of NA cessation.Methods: This prospective multicentre study enrolled 135 CHB patients who stopped entecavir or tenofovir after achieving viral remission for a median of 25.2 months. All patients stopped NA with negative HBeAg and undetectable viral DNA, and were then observed for clinical relapse and HBsAg loss. Predictors including HBsAg and HBcrAg levels were explored using Cox proportional hazard model and weighted to develop a risk score.Results: During a median follow‐up of 25.9 months, clinical relapse and HBsAg loss occurred in 66 and eight patients, respectively, with a 5‐year cumulative incidence of 56.1% (95% CI 46.7‐66.0%) and 8.8% (95% CI 4.3‐17.4%), respectively. HBcrAg was an independent relapse predictor, as well as HBsAg, age, ALT and tenofovir use. A score (SCALE‐B) was calculated by the equation of 35*HBsAg (log IU/mL) + 20*HBcrAg (log U/mL) + 2*age (year) + ALT (U/L) + 40 for tenofovir use. The concordance rates for clinical relapse were 0.87, 0.88, 0.87, 0.85 and 0.90 at 1, 2, 3, 4 and 5 years, respectively. Moreover, HBsAg loss occurred exclusively in low‐risk patients predicted by the score.Conclusions: Serum HBcrAg and HBsAg levels were independent predictors of off‐NA relapse and can be factored into a risk score to guide treatment cessation in patients with CHB.

1 March 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
LCLi-Chun Chang
Li-Chun Chang
CCChi-Yang Chang
Chi-Yang Chang
CCChi-Yi Chen
Chi-Yi Chen
CTCheng-Hao Tseng
Cheng-Hao Tseng
PCPeng-Jen Chen
Peng-Jen Chen
HCHan-Mo Chiu
Han-Mo Chiu
Although cold snare polypectomy (CSP) is considered effective in reducing delayed postpolypectomy bleeding risk, direct evidence supporting its safety in the general population remains lacking. To clarify whether CSP would reduce delayed bleeding risk after polypectomy compared with hot snare polypectomy (HSP) in the general population. Multicenter randomized controlled study. (ClinicalTrials.gov: NCT03373136). 6 sites in Taiwan, July 2018 through July 2020. Participants aged 40 years or older with polyps of 4 to 10 mm. CSP or HSP to remove polyps of 4 to 10 mm. The primary outcome was the delayed bleeding rate within 14 days after polypectomy. Severe bleeding was defined as a decrease in hemoglobin concentration of 20 g/L or more, requiring transfusion or hemostasis. Secondary outcomes included mean polypectomy time, successful tissue retrieval, en bloc resection, complete histologic resection, and emergency service visits. A total of 4270 participants were randomly assigned (2137 to CSP and 2133 to HSP). Eight patients (0.4%) in the CSP group and 31 (1.5%) in the HSP group had delayed bleeding (risk difference, -1.1% [95% CI, -1.7% to -0.5%]). Severe delayed bleeding was also lower in the CSP group (1 [0.05%] vs. 8 [0.4%] events; risk difference, -0.3% [CI, -0.6% to -0.05%]). Mean polypectomy time (119.0 vs. 162.9 seconds; difference in mean, -44.0 seconds [CI, -53.1 to -34.9 seconds]) was shorter in the CSP group, although successful tissue retrieval, en bloc resection, and complete histologic resection did not differ. The CSP group had fewer emergency service visits than the HSP group (4 [0.2%] vs. 13 [0.6%] visits; risk difference, -0.4% [CI, -0.8% to -0.04%]). An open-label, single-blind trial. Compared with HSP, CSP for small colorectal polyps significantly reduces the risk for delayed postpolypectomy bleeding, including severe events. Boston Scientific Corporation.

1 November 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JYJen-Hao Yeh
Jen-Hao Yeh
CTCheng-Hao Tseng
Cheng-Hao Tseng
RHRu-Yi Huang
Ru-Yi Huang
CLChih-Wen Lin
Chih-Wen Lin
CLChing-Tai Lee
Ching-Tai Lee
Wen-Lun WangWen-Lun Wang
Wen-Lun Wang

1 May 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
SKSahith Kudaravalli
Sahith Kudaravalli
DHDaniel Q Huang
Daniel Q Huang
MYMing-Lun Yeh
Ming-Lun Yeh
LTLindsey Trinh
Lindsey Trinh
PTP C Tsai
P C Tsai
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen

28 October 2022 in JHEP Reports
Verified
Journal Article
Open access
CTCheng-Hao Tseng
Cheng-Hao Tseng
TCTzu-Haw Chen
Tzu-Haw Chen
JWJia-Ling Wu
Jia-Ling Wu
TLTeng-Yu Lee
Teng-Yu Lee
JBJohn A. Borghi
John A. Borghi
YHYao-Chun Hsu
Yao-Chun Hsu
The risk of serious clinical outcomes following cessation of nucleos(t)ide analogues (NUCs) in individuals with chronic hepatitis B remains poorly characterized. This systematic review and meta-analysis aimed to evaluate current literature on this issue. We searched PubMed, Embase, and Web of Science for NUC stop studies that noted clinical outcomes published between January 1, 2006 and August 18, 2022. We performed meta-research analyses to examine the relationships of reported outcomes with study designs and characteristics and also pooled studies with non-overlapping populations to provide risk estimates for the proportions of (1) severe hepatitis flares or hepatic decompensation or (2) hepatitis flare-related death or liver transplantation. The meta-research analysis included 50 studies of highly heterogeneous designs and characteristics. We found that reporting of safety outcomes varied widely according to outcome definition, follow-up duration, and sample size. Only ten studies prespecified safety events as the study outcome, and only four had an outcome definition to include hepatic insufficiency, a follow-up duration >12 months, and a sample size >100 patients. We further pooled 15 studies with 4,525 individuals and estimated that severe hepatitis flares or decompensation would occur in 1.21% (95% CI 0.70–2.08%), with significant heterogeneity (I2 = 54%, p <0.01), while hepatitis flare-related death or liver transplantation would occur in 0.37% (95% CI 0.20–0.67%), without significant heterogeneity (I2 = 0.00%, p = 1.00). Current literature on the risk of serious clinical outcomes following NUC cessation is very limited and highly heterogeneous. Pooled analyses of available data found approximately 1% of patients who stopped NUCs developed severe flares or hepatic decompensation. Current literature regarding the safety concerns surrounding NUC cessation for individuals with chronic hepatitis B is limited and heterogeneous in designs and characteristics, and thus should be interpreted with great caution. Based on currently available data, the proportion of patients that develop severe hepatitis flares or hepatic decompensation was estimated at 1.21% and that of flare-related death or liver transplantation at 0.37%. Our findings are important for individuals receiving nucleos(t)ide analogues for hepatitis B virus infection because we not only pooled currently available data to estimate the risk of serious clinical adverse events following treatment cessation but also uncovered critical limitations of existing literature regarding the safety of finite therapy.

1 October 2018 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CTCheng-Hao Tseng
Cheng-Hao Tseng
YHYao-Chun Hsu
Yao-Chun Hsu
CCChi-Yang Chang
Chi-Yang Chang
TTTai-Chung Tseng
Tai-Chung Tseng
MWMing-Shiang Wu
Ming-Shiang Wu
JKJia-Horng Kao
Jia-Horng Kao
The predictors of off-therapy response in patients treated with neucleos(t)ide analogue (NA) have not been elucidated. It remained unexplored whether serum level of hepatitis B core antibody (anti-HBc) at the end of NA therapy was associated with relapse risks. This prospective study monitored 82 chronic hepatitis B (CHB) patients after discontinuing entecavir. All patients had been treated for 3 years or longer and serologically negative for viral DNA and HBeAg at treatment cessation. Patients were monitored for virological relapse (viral DNA > 2000 IU/mL), and clinical relapse (serum alanine aminotransferase > 80 U/L plus virological relapse). The association between anti-HBc levels and the risk of relapse was assessed by the Cox analysis. Clinical and virological relapses occurred in 29 and 60 participants, respectively, with the cumulative incidences of 23.7% (95% CI, 15.8-34.6%) and 62.0% (95% CI, 51.5-72.5%) at 1 year, and 36.2% (95% CI, 26.2-48.4%) and 78.8% (95% CI, 68.2-87.8%) at 2 years, respectively. There was a trend for an inverse association between anti-HBc and clinical relapse (crude hazard ratio [HR], 0.50; 95% CI, 0.24-1.05). All 3 patients with the level <100 IU/mL had a rapid clinical relapse (P = 0.002). This trend remained after adjustment for HBsAg and age (adjusted HR 0.50, 95% CI, 0.24-1.03). On the other hand, anti-HBc quantity was unrelated to virological relapse (crude HR, 0.97; 95% CI, 0.58-1.62; adjusted HR, 0.97; 95% CI, 0.58-1.60). This pilot study suggests a trend for an inverse association between anti-HBc levels and clinical relapse in CHB patients off entecavir.